Despite the possible beneficial use of apoC1 as a CETP inhibitor against atherosclerosis, strategies aiming at inducing very high plasma levels of apoC1 would not be relevant because of the possible hypertriglyceridemic effect [10]. This evidence concerns the gene APOC1 and atherosclerosis.